加味温胆片治疗痰湿阻遏型血脂异常临床疗效观察
|
摘要
目的:观察加味温胆片治疗痰湿阻遏型血脂异常的临床疗效。
方法:临床观察60例中医证候属于痰湿阻遏型血脂异常患者,采用随机对照法分成治疗组与对照组各30例。治疗组给予加味温胆片治疗,对照组给予血脂康胶囊治疗,疗程为4周,观察治疗前后血脂、C.反应蛋白(C-reaction proteinCRP)水平及中医证候积分改善情况。
结果:经治疗4周后,加味温胆片能显著降低痰湿阻遏型血脂异常患者治疗前后总胆固醇(Total cholesterol,TC)、甘油三酯(Triglyceride,TG)水平,与血脂康胶囊对照组比较,控制血脂水平总疗效差异无统计学意义(P＞0.05),并且在降低TG及升高高密度脂蛋白胆固醇水平(High densitylipoproten-cholesterol,HDL-C)、载脂蛋白AⅠ(apol ipoproteinAⅠ,apoAⅠ)水平方面疗效与对照组相当(P＞0.05),但在降低TC、低密度脂蛋白胆固醇(Lowdensi ty lipoproten-cholesterol,LDL-C)及载脂蛋白B(apol ipoproteinB,apoB)水平方面疗效不及对照组(P＜0.01或＜0.05);加味温胆片治疗组改善中医证候积分优于对照组(P＜0.05),并能显著改善头重如裹、胸闷、失眠、口淡、食少等症状(P＜0.01或P＜0.05);加味温胆片虽未能显示明显降低CRP的水平(P＞0.05),但有使CRP水平降低的趋势。
结论:加味温胆片可有效降低痰湿阻遏型血脂异常患者的血脂水平,改善患者临床症状,因此可作为临床上治疗痰湿阻遏型血脂异常的理想药物。
Objective:To observe the clinical efficacy of JiaWeiWenDanPian in the treatment of Phlegm-Damp Syndrome in Dyslipidemia.
Methods:Sixty patients of Phlegm-Damp Syndrome in Dyslipidemia were divided into therapeutic group(30 cases)and control group(30 cases)randomly.The patients of the therapeutic group were received JiaWeiWenDanPian and in the control group were given Xuezhikang capsule.The difference of the blood lipid levels,C-reaction protein(CRP)and the syndrome of Traditional Chinese Medicine scores in all the patients were observed between pre and post treatment.
Results:After 4 weeks,it showed that JiaWeiWenDanPian could decrease the level of serum Total cholesterol(TC)and Triglyceride(TG).There was no significant difference on the aspects of total therapeutic effect of blood lipid between two.the groups(P＞0.05).Compared with the level of blood lipid between two the groups,the result was evaluated there was no significant difference in lowering the level of TG and increasing the level of High-density lipoprotein cholesterol(HDL-C)and Apolipoprotein A I(apoA I)(P＞0.05),but the levels of TC,Low-density lipoprotein cholesterol(LDL-C)and Apolipoprotein B(apoB)were obviously higher than those in control group(P＜0.01 or＜0.05).The improved rate of traditional Chinese medical syndrome scores in the therapeutic group was significantly higher than that in the control group,and there was significant difference between the two groups(P＜0.05).The improvement of head heaviness,chest distress,insomnia,bland taste and poor appetite in the therapeutic group was superior to that in the control group(P＜0.01 or P＜0.05).There was a decreasing trend in level of CRP,but the decrease was not statistically significant(P＞0.05).
Conclusion:JiaWeiWenDanPian could remarkably decrease the blood lipid level of Phlegm-Damp Syndrome in Dyslipidemia and improve clinical symptoms.So JiaWeiWenDanPian is An ideal lipid lowering agents.
方法:临床观察60例中医证候属于痰湿阻遏型血脂异常患者,采用随机对照法分成治疗组与对照组各30例。治疗组给予加味温胆片治疗,对照组给予血脂康胶囊治疗,疗程为4周,观察治疗前后血脂、C.反应蛋白(C-reaction proteinCRP)水平及中医证候积分改善情况。
结果:经治疗4周后,加味温胆片能显著降低痰湿阻遏型血脂异常患者治疗前后总胆固醇(Total cholesterol,TC)、甘油三酯(Triglyceride,TG)水平,与血脂康胶囊对照组比较,控制血脂水平总疗效差异无统计学意义(P＞0.05),并且在降低TG及升高高密度脂蛋白胆固醇水平(High densitylipoproten-cholesterol,HDL-C)、载脂蛋白AⅠ(apol ipoproteinAⅠ,apoAⅠ)水平方面疗效与对照组相当(P＞0.05),但在降低TC、低密度脂蛋白胆固醇(Lowdensi ty lipoproten-cholesterol,LDL-C)及载脂蛋白B(apol ipoproteinB,apoB)水平方面疗效不及对照组(P＜0.01或＜0.05);加味温胆片治疗组改善中医证候积分优于对照组(P＜0.05),并能显著改善头重如裹、胸闷、失眠、口淡、食少等症状(P＜0.01或P＜0.05);加味温胆片虽未能显示明显降低CRP的水平(P＞0.05),但有使CRP水平降低的趋势。
结论:加味温胆片可有效降低痰湿阻遏型血脂异常患者的血脂水平,改善患者临床症状,因此可作为临床上治疗痰湿阻遏型血脂异常的理想药物。
Objective:To observe the clinical efficacy of JiaWeiWenDanPian in the treatment of Phlegm-Damp Syndrome in Dyslipidemia.
Methods:Sixty patients of Phlegm-Damp Syndrome in Dyslipidemia were divided into therapeutic group(30 cases)and control group(30 cases)randomly.The patients of the therapeutic group were received JiaWeiWenDanPian and in the control group were given Xuezhikang capsule.The difference of the blood lipid levels,C-reaction protein(CRP)and the syndrome of Traditional Chinese Medicine scores in all the patients were observed between pre and post treatment.
Results:After 4 weeks,it showed that JiaWeiWenDanPian could decrease the level of serum Total cholesterol(TC)and Triglyceride(TG).There was no significant difference on the aspects of total therapeutic effect of blood lipid between two.the groups(P＞0.05).Compared with the level of blood lipid between two the groups,the result was evaluated there was no significant difference in lowering the level of TG and increasing the level of High-density lipoprotein cholesterol(HDL-C)and Apolipoprotein A I(apoA I)(P＞0.05),but the levels of TC,Low-density lipoprotein cholesterol(LDL-C)and Apolipoprotein B(apoB)were obviously higher than those in control group(P＜0.01 or＜0.05).The improved rate of traditional Chinese medical syndrome scores in the therapeutic group was significantly higher than that in the control group,and there was significant difference between the two groups(P＜0.05).The improvement of head heaviness,chest distress,insomnia,bland taste and poor appetite in the therapeutic group was superior to that in the control group(P＜0.01 or P＜0.05).There was a decreasing trend in level of CRP,but the decrease was not statistically significant(P＞0.05).
Conclusion:JiaWeiWenDanPian could remarkably decrease the blood lipid level of Phlegm-Damp Syndrome in Dyslipidemia and improve clinical symptoms.So JiaWeiWenDanPian is An ideal lipid lowering agents.
引文
[1]中华人民共和国卫生部.2006中国卫生统计年鉴.北京:中国协和医科大学出版社,2006.
[2]He J,Gu DF,Wu XG,et al.Major Causes of Death among Men and Women in China.N Engl J Med,2005;353(11):1124-1134.
[3]Zhou B,Zhang H,Wu Y,et al.Ecological analysis of the association between incidence and risk factors of coronary heart disease and stroke in Chinese populations.CVD Prevention,1998;1(3):207-216.
[4]Wu Z.Yao C.Zhao D,et al.A collaborative study on trend and determinants in cardiovascular diseases in China,Part Ⅰ:morbidity and mortality monitoring Circulation,2001:103(3):462-468.
[5]陶寿淇,武阳丰,主编.医疗卫生人员心血管病防治知识.北京:中国友谊出版公司,2000.
[6]赵冬,吴兆苏,王薇,等.北京地区1984-1997年急性冠心病事件发病率变化趋势(中国MONICA方案的研究).中华心血管病杂志,2000;28(1):14-17.
[7]王文化,赵冬,吴桂贤,等.北京市1984-1999年人群脑卒中发病率变化趋势.中华流行病学杂志,2001;22(4):269-272.
[8]王文化,赵冬,吴桂贤,等.北京市1984-1999年急性脑出血和脑血栓发病率变化趋势.中华流行病学杂志,2002;23(5):352-355.
[9]刘静,赵冬,吴兆苏,等.低密度脂蛋白胆固醇与心血管病发病关系的前瞻性研究.中华心血管病杂志,2001;29(9):561-565.
[10]李莹,陈志红,周北凡,等.血脂和脂蛋白水平对我国中年人群缺血性心血管病事件的预测作用.中华心血管病杂志,2004;32(7):643-647.
[11]武阳丰,赵冬,周北凡,等.中国人群血脂异常诊治和分层方案的研究.中华心血管病杂志,2007(35):428-433.
[12]国家九五攻关课题协作组.我国心血管病发病趋势预测及21世纪预防策略的研究.医学研究通讯,2003;32(1):2-5.
[13]王薇,赵冬,刘静,等.中国35-64岁人群胆固醇水平与10年心血管病发病危险的前瞻性研究.中华心血管病杂志,2006;34(2):169-173.
[14]李莹,陈志红,周北凡,等.血脂和脂蛋白水平对我国中年人群缺血性心血管病事件的预测作用.中华心血管病杂志,2004;32(7):643-647.
[15]王薇,赵冬,吴兆苏,等.中国11省市35-64岁人群血清甘油三酯分布特点及与其他心血管病危险因素关系的研究.中华流行病学杂志,2001;22(1):26-29.
[16]Key A.Serum cholesterol response to dietary cholesterol.Am J Clin Nutr,1984;40(2):351-360.
[17]Hjermann I,Velve Byre K,Holme I,et al.Effect of diet and smoking intervention on the incidence of coronary disease.Lancet,1981;2(8259):1303.
[18]The Scandinavian Simvastatin Survival Study Croup.Randomised trial of lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study(4S).Lancet,1994;344(8934):1383-1389.
[19]Sacks FM,Pfeffer MA,Moye LA,et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.Cholesterol and Recurrent Events Trial investigators.N Engl J Med,1996;335(14):1001-1009.
[20]杨惠民,盛彤,韩丽蓓.调脂通脉颗粒改善老年高脂血症痰瘀证患者脂质代谢作用的研究[J].中华现代医学与临床,2006;3(8):59-60.
[21]杨俐,陈学忠,尹方.高脂血症痰浊病机探讨[J].中医药临床杂志,2005:17(6):539-540.
[22]韩崇伟,健脾化痰治疗高脂血症的理论探讨[J].山东医药,2006;46(10):78.
[23]龚一萍,宋国平.试论脏腑功能失调与高脂血症形成的相关性[J].中国中医药信息杂志,2001;8(8):7-8.
[24]高红勤,沈逸辛,钱建明.补肾降脂丸治疗高脂血症的临床观察[J].中国中西医结合杂志,2001;21(3):217-218.
[25]杨秀捷,张晨,赵冰.从脾论治高脂血症60例临床观察[J].北京中医,2006:25(1):1-13.
[26]朱涛,郭仲之.从“脾主运化”认识高脂血症与痰浊的关系[J].中华综合医学,2002;3(2):159.
[27]张万方.从脾胃角度浅谈血脂代谢异常[J].中医药学刊,2003;21(12):2113-2114.
[28]王永林.高脂血症病在心脉,根在肝、脾、肾[J].中国医学研究与临床,2006;4(5):80-81.
[29]张金生.高脂血症从肝论治初探[J].新中医,2006;38(11):6-8.
[30]杨惠民,盛彤,韩丽蓓.调脂通脉颗粒改善老年高脂血症痰瘀证患者脂质代谢作用的研究[J].中华现代医学与临床,2006;3(8):59-60.
[31]杨俐,陈学忠,尹方.高脂血症痰浊病机探讨[J].中医药临床杂志,2005;17(6):539-540.
[32]韩崇伟,健脾化痰治疗高脂血症的理论探讨[J].山东医药,2006;46(10):78.
[33]尹亚东.浅析从“痰瘀论治高脂血症”[J].甘肃中医,2006;19,(11):9-10.
[34]陈晓云,沈梅,赵敬东,等.调脂散胶囊治疗老年原发性高脂血症的疗效观察[J].辽宁中医杂志,2001;28(6):353-354.
[35]鲍荣琦.调脂汤治疗高脂血症32例[J],南京中医药大学学报(自然科学版),2002;18(6):373-374.
[36]吴立文,金智生,浦斌红.健脾降脂灵治疗高脂血症临床观察[J].中国中医药信息杂志,2002;9(12):8-10.
[37]张琦,江泳,陈建杉.苓桂术甘加味汤对高脂血症大鼠脂代谢及血液流变学影响的实验研究[J].中国中医基础医学杂志,2003;9(9):36-39.
[38]杨应战.柴胡疏肝散加昧治疗高脂血症70例[J].陕西中医,2005;26(7):655-656.
[39]刘孟安,姜学连,赵岩,等.调脂合剂治疗高脂血症的临床研究[J].中国微循环,2005;9(2):130-131.
[40]张金钊.舒肝调脂汤治疗脂肪肝30例临床观察[J].国医论坛,2006;21(4):24-25.
[41]毛大鹏,刘汝金,齐有胜,等.健脾利湿法治疗高脂血症42例的临床观察[J].北京中医,2006;25(10):599-602.
[42]刘冬立,王文利,郑宏.复方降脂茶治疗原发性高脂血症(痰浊内阻证)的临床研究[J].北京中医,2006;5(9):523-526.
[43]陈支红.化痰除湿法治疗高脂血症38例[J].现代中西医结合杂志,2003:12(21):2333-2334.
[44]叶勇,梅国强,刘松林,等.化痰活血方对高脂血症大鼠血脂代谢的影响及其抗氧化作用[J].时珍国医国药,2005;16(10):968-969.
[45]叶勇,赵春霞,汪道文,等.化痰活血方调脂及保护内皮细胞的作用[J].中国临床康复,2006;10(19):74-77.
[46]叶勇,梅国强,刘松林,等.化痰活血方对高脂血症大鼠血液流变学的影响[J].湖北中医学院学报,2005;7(3):11-13.
[47]刘炜.血府逐瘀胶囊治疗高脂血症43例临床研究[J].北京中医,2003;22(5):63-64.
[48]焦亚斌,李冀,肖洪彬.活血化瘀法对实验性高脂血症大鼠调血脂作用的研究[J].中医药信息,2002;19(6):55-56.
[49]邸毅,刘潮.血脂康胶囊治疗高脂血症的临床观察[J].实用新医学,2006;7(12):1077.
[50]张西春,曹晓莉.脂必妥治疗高脂血症的疗效观察[J].西北药学杂志,2006;21(5):223-224.
[51]World Health Organisation.European Collaborative Group.European collaborative trial of multifactorial prevention of coronary heart disease.Lancet,1986,1(8486):869.
[52]中国成人血脂异常防治指南[J].中华心血管病杂志,2007;35(5):390.
[53]Sacks FM.Pfeffer MA.Moye LA,et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level.Cholesterol and Recurrent Evevts Trial investigators.N Engl J Med,1996,335(14):1001-1009.
[54]The Long-Term Intervention with Pravastatin in Lschaemic disease(LIPID)study group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.N Engl J Med,1998,339(19):1349-1357.
155]Sever PS,Dahlof B,Poulter NR,et al.ASCOT inverstigators.Prevention of coronary and stroke events with arorvastatin in hypertensive patients who have average or lower-than-average cholesterol cncentations,in the Anglo-Scandinavan Cardiac Outcomes Trial-Lipid Lowering Arm(ASCOT-LLA):a multicentre randomized controlled trail.Lancet,2003,361(9364):1149-1158.
[56]Rubins HB,Robins SJ,Collins D,et al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.N Engl J Med,1999,341(6):410-418.
[57]The Lipid Research Clinics Program.The Lipid research clinics coronary primary prevention trial results.Ⅰ.Reduction in incidence of coronary heart disease.JAMA,1984,251(3):351-358.
[58]The Lipid Research Clinics Program.The Lipid research clinics coronary primary prevention trial results.Ⅱ.Relationship of reduction in incidence of coronary heart disease to cholesterol lowering.JAMA,1984,251(3):365-370.
[59]赵水平.血脂临床检测及其意义.中国临床医生,2003;31(10):27-29.
[60]Gotto AM Jr,Brinton EA.Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease:a working group report and update.J Am Coil Cardiol,2004,43(5):717-724.
[61]Duffy D,Racier DJ.Emerging therapies targeting hish-density lipoprotein metabolism and reverse cholesterol transport.Circulation,2006:113(8):1140-1150.
[62]Assmann G,Schulte H.Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease(the PROCAM experience).Am J Cardiol,1992:70(7):733-737.
[63]Walldius G,Jungner I,Holme I,et al.High apolipoprotein B,low apolipoprotein A-I.and improvement in the prediction of fatal myocardial infarction(AMORIS study):a prospective study.Lancet,2001;358(9298):2026-2033.
[64]杜开春.超敏C反应蛋白与血脂联合检测的临床价值[J].检验医学与临床,2007;4(6):468-469.
[65]赵花,张红,李娇颖.高血脂患者237例血清hS-CRP测定结果分析[J].第四军医大学学报,2007;28(12):1103.
[66]Menotti A,Blackburn H,Kromhout D,et al.Changes in population cholesterol levels and coronary heart disease deaths in seven countries.Eur Heart J,1997:18(4):566-571.
[67]中华人民共和国卫生部.中药新药临床研究指导原则(第二辑).1993,85-89.
[68]黄兆胜.中药学,北京:人民卫生出版社,2000;12.
[69]洪行球,沃兴德.半夏降血脂作用研究[J].浙江中医学院学报,1995;19(2):28.
[70]刘雪莉,李兰妹,姚雪艳.桔皮果胶对家兔实验性动脉粥样硬化的形态学影响[J].现代应用药学,1992;9(3):106.
[71]陈红.甘草药理作用概述[J].海峡药学,2005;17(4):37-41.
[72]郭淑睿,曹永荣,高光英.郁金对实验性高脂血症动物血脂含量的影响[J].中医药研究,1998;14(3):32.
[73]降脂中药概述[J].中华实用中西医杂志,2001;14(7):1446.
[74]朱燕,李长龄,王银叶.血脂康对高脂家兔、鹌鹑模型的降脂作用[J].中国药学杂志,1995:30(11):656-659.
[75]李长龄,李雅芳,侯中林.血脂康的毒性试验研究[J].中国药理学会通讯,1995;12:121.
[76]王俊显,苏梅者,陆宗良,等.血脂康胶囊治疗高脂血症临床观察[J].中国实验方剂学杂志,1995;1(1):37-41.
[77]寇文怠,陆宗良,郭静萱,等.血脂康对原发性高脂血症的临床疗效[J].中华内科杂志,1997:36(8):529-531.
[78]血脂康调整血脂对冠心病二级预防研究协作组.中国冠心病二级预防研究。中华心血管病杂志,2005;33(2):109-115.
[79]吴研.对高脂血症“病在血液,根在脾胃”的认识[J].中医杂志,2004;45(2):155
[80]宋剑南,刘东远.高脂血症与中医痰浊关系的实验研究[J].中国中医基础医学杂志,1995;1(1):49-51.
[81]刘松林,王平,张茂林,等.痰邪致病机理的现代研究思路与方法探讨[J].中医杂志,2003;44(1):5-7.
[2]He J,Gu DF,Wu XG,et al.Major Causes of Death among Men and Women in China.N Engl J Med,2005;353(11):1124-1134.
[3]Zhou B,Zhang H,Wu Y,et al.Ecological analysis of the association between incidence and risk factors of coronary heart disease and stroke in Chinese populations.CVD Prevention,1998;1(3):207-216.
[4]Wu Z.Yao C.Zhao D,et al.A collaborative study on trend and determinants in cardiovascular diseases in China,Part Ⅰ:morbidity and mortality monitoring Circulation,2001:103(3):462-468.
[5]陶寿淇,武阳丰,主编.医疗卫生人员心血管病防治知识.北京:中国友谊出版公司,2000.
[6]赵冬,吴兆苏,王薇,等.北京地区1984-1997年急性冠心病事件发病率变化趋势(中国MONICA方案的研究).中华心血管病杂志,2000;28(1):14-17.
[7]王文化,赵冬,吴桂贤,等.北京市1984-1999年人群脑卒中发病率变化趋势.中华流行病学杂志,2001;22(4):269-272.
[8]王文化,赵冬,吴桂贤,等.北京市1984-1999年急性脑出血和脑血栓发病率变化趋势.中华流行病学杂志,2002;23(5):352-355.
[9]刘静,赵冬,吴兆苏,等.低密度脂蛋白胆固醇与心血管病发病关系的前瞻性研究.中华心血管病杂志,2001;29(9):561-565.
[10]李莹,陈志红,周北凡,等.血脂和脂蛋白水平对我国中年人群缺血性心血管病事件的预测作用.中华心血管病杂志,2004;32(7):643-647.
[11]武阳丰,赵冬,周北凡,等.中国人群血脂异常诊治和分层方案的研究.中华心血管病杂志,2007(35):428-433.
[12]国家九五攻关课题协作组.我国心血管病发病趋势预测及21世纪预防策略的研究.医学研究通讯,2003;32(1):2-5.
[13]王薇,赵冬,刘静,等.中国35-64岁人群胆固醇水平与10年心血管病发病危险的前瞻性研究.中华心血管病杂志,2006;34(2):169-173.
[14]李莹,陈志红,周北凡,等.血脂和脂蛋白水平对我国中年人群缺血性心血管病事件的预测作用.中华心血管病杂志,2004;32(7):643-647.
[15]王薇,赵冬,吴兆苏,等.中国11省市35-64岁人群血清甘油三酯分布特点及与其他心血管病危险因素关系的研究.中华流行病学杂志,2001;22(1):26-29.
[16]Key A.Serum cholesterol response to dietary cholesterol.Am J Clin Nutr,1984;40(2):351-360.
[17]Hjermann I,Velve Byre K,Holme I,et al.Effect of diet and smoking intervention on the incidence of coronary disease.Lancet,1981;2(8259):1303.
[18]The Scandinavian Simvastatin Survival Study Croup.Randomised trial of lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study(4S).Lancet,1994;344(8934):1383-1389.
[19]Sacks FM,Pfeffer MA,Moye LA,et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.Cholesterol and Recurrent Events Trial investigators.N Engl J Med,1996;335(14):1001-1009.
[20]杨惠民,盛彤,韩丽蓓.调脂通脉颗粒改善老年高脂血症痰瘀证患者脂质代谢作用的研究[J].中华现代医学与临床,2006;3(8):59-60.
[21]杨俐,陈学忠,尹方.高脂血症痰浊病机探讨[J].中医药临床杂志,2005:17(6):539-540.
[22]韩崇伟,健脾化痰治疗高脂血症的理论探讨[J].山东医药,2006;46(10):78.
[23]龚一萍,宋国平.试论脏腑功能失调与高脂血症形成的相关性[J].中国中医药信息杂志,2001;8(8):7-8.
[24]高红勤,沈逸辛,钱建明.补肾降脂丸治疗高脂血症的临床观察[J].中国中西医结合杂志,2001;21(3):217-218.
[25]杨秀捷,张晨,赵冰.从脾论治高脂血症60例临床观察[J].北京中医,2006:25(1):1-13.
[26]朱涛,郭仲之.从“脾主运化”认识高脂血症与痰浊的关系[J].中华综合医学,2002;3(2):159.
[27]张万方.从脾胃角度浅谈血脂代谢异常[J].中医药学刊,2003;21(12):2113-2114.
[28]王永林.高脂血症病在心脉,根在肝、脾、肾[J].中国医学研究与临床,2006;4(5):80-81.
[29]张金生.高脂血症从肝论治初探[J].新中医,2006;38(11):6-8.
[30]杨惠民,盛彤,韩丽蓓.调脂通脉颗粒改善老年高脂血症痰瘀证患者脂质代谢作用的研究[J].中华现代医学与临床,2006;3(8):59-60.
[31]杨俐,陈学忠,尹方.高脂血症痰浊病机探讨[J].中医药临床杂志,2005;17(6):539-540.
[32]韩崇伟,健脾化痰治疗高脂血症的理论探讨[J].山东医药,2006;46(10):78.
[33]尹亚东.浅析从“痰瘀论治高脂血症”[J].甘肃中医,2006;19,(11):9-10.
[34]陈晓云,沈梅,赵敬东,等.调脂散胶囊治疗老年原发性高脂血症的疗效观察[J].辽宁中医杂志,2001;28(6):353-354.
[35]鲍荣琦.调脂汤治疗高脂血症32例[J],南京中医药大学学报(自然科学版),2002;18(6):373-374.
[36]吴立文,金智生,浦斌红.健脾降脂灵治疗高脂血症临床观察[J].中国中医药信息杂志,2002;9(12):8-10.
[37]张琦,江泳,陈建杉.苓桂术甘加味汤对高脂血症大鼠脂代谢及血液流变学影响的实验研究[J].中国中医基础医学杂志,2003;9(9):36-39.
[38]杨应战.柴胡疏肝散加昧治疗高脂血症70例[J].陕西中医,2005;26(7):655-656.
[39]刘孟安,姜学连,赵岩,等.调脂合剂治疗高脂血症的临床研究[J].中国微循环,2005;9(2):130-131.
[40]张金钊.舒肝调脂汤治疗脂肪肝30例临床观察[J].国医论坛,2006;21(4):24-25.
[41]毛大鹏,刘汝金,齐有胜,等.健脾利湿法治疗高脂血症42例的临床观察[J].北京中医,2006;25(10):599-602.
[42]刘冬立,王文利,郑宏.复方降脂茶治疗原发性高脂血症(痰浊内阻证)的临床研究[J].北京中医,2006;5(9):523-526.
[43]陈支红.化痰除湿法治疗高脂血症38例[J].现代中西医结合杂志,2003:12(21):2333-2334.
[44]叶勇,梅国强,刘松林,等.化痰活血方对高脂血症大鼠血脂代谢的影响及其抗氧化作用[J].时珍国医国药,2005;16(10):968-969.
[45]叶勇,赵春霞,汪道文,等.化痰活血方调脂及保护内皮细胞的作用[J].中国临床康复,2006;10(19):74-77.
[46]叶勇,梅国强,刘松林,等.化痰活血方对高脂血症大鼠血液流变学的影响[J].湖北中医学院学报,2005;7(3):11-13.
[47]刘炜.血府逐瘀胶囊治疗高脂血症43例临床研究[J].北京中医,2003;22(5):63-64.
[48]焦亚斌,李冀,肖洪彬.活血化瘀法对实验性高脂血症大鼠调血脂作用的研究[J].中医药信息,2002;19(6):55-56.
[49]邸毅,刘潮.血脂康胶囊治疗高脂血症的临床观察[J].实用新医学,2006;7(12):1077.
[50]张西春,曹晓莉.脂必妥治疗高脂血症的疗效观察[J].西北药学杂志,2006;21(5):223-224.
[51]World Health Organisation.European Collaborative Group.European collaborative trial of multifactorial prevention of coronary heart disease.Lancet,1986,1(8486):869.
[52]中国成人血脂异常防治指南[J].中华心血管病杂志,2007;35(5):390.
[53]Sacks FM.Pfeffer MA.Moye LA,et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level.Cholesterol and Recurrent Evevts Trial investigators.N Engl J Med,1996,335(14):1001-1009.
[54]The Long-Term Intervention with Pravastatin in Lschaemic disease(LIPID)study group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.N Engl J Med,1998,339(19):1349-1357.
155]Sever PS,Dahlof B,Poulter NR,et al.ASCOT inverstigators.Prevention of coronary and stroke events with arorvastatin in hypertensive patients who have average or lower-than-average cholesterol cncentations,in the Anglo-Scandinavan Cardiac Outcomes Trial-Lipid Lowering Arm(ASCOT-LLA):a multicentre randomized controlled trail.Lancet,2003,361(9364):1149-1158.
[56]Rubins HB,Robins SJ,Collins D,et al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.N Engl J Med,1999,341(6):410-418.
[57]The Lipid Research Clinics Program.The Lipid research clinics coronary primary prevention trial results.Ⅰ.Reduction in incidence of coronary heart disease.JAMA,1984,251(3):351-358.
[58]The Lipid Research Clinics Program.The Lipid research clinics coronary primary prevention trial results.Ⅱ.Relationship of reduction in incidence of coronary heart disease to cholesterol lowering.JAMA,1984,251(3):365-370.
[59]赵水平.血脂临床检测及其意义.中国临床医生,2003;31(10):27-29.
[60]Gotto AM Jr,Brinton EA.Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease:a working group report and update.J Am Coil Cardiol,2004,43(5):717-724.
[61]Duffy D,Racier DJ.Emerging therapies targeting hish-density lipoprotein metabolism and reverse cholesterol transport.Circulation,2006:113(8):1140-1150.
[62]Assmann G,Schulte H.Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease(the PROCAM experience).Am J Cardiol,1992:70(7):733-737.
[63]Walldius G,Jungner I,Holme I,et al.High apolipoprotein B,low apolipoprotein A-I.and improvement in the prediction of fatal myocardial infarction(AMORIS study):a prospective study.Lancet,2001;358(9298):2026-2033.
[64]杜开春.超敏C反应蛋白与血脂联合检测的临床价值[J].检验医学与临床,2007;4(6):468-469.
[65]赵花,张红,李娇颖.高血脂患者237例血清hS-CRP测定结果分析[J].第四军医大学学报,2007;28(12):1103.
[66]Menotti A,Blackburn H,Kromhout D,et al.Changes in population cholesterol levels and coronary heart disease deaths in seven countries.Eur Heart J,1997:18(4):566-571.
[67]中华人民共和国卫生部.中药新药临床研究指导原则(第二辑).1993,85-89.
[68]黄兆胜.中药学,北京:人民卫生出版社,2000;12.
[69]洪行球,沃兴德.半夏降血脂作用研究[J].浙江中医学院学报,1995;19(2):28.
[70]刘雪莉,李兰妹,姚雪艳.桔皮果胶对家兔实验性动脉粥样硬化的形态学影响[J].现代应用药学,1992;9(3):106.
[71]陈红.甘草药理作用概述[J].海峡药学,2005;17(4):37-41.
[72]郭淑睿,曹永荣,高光英.郁金对实验性高脂血症动物血脂含量的影响[J].中医药研究,1998;14(3):32.
[73]降脂中药概述[J].中华实用中西医杂志,2001;14(7):1446.
[74]朱燕,李长龄,王银叶.血脂康对高脂家兔、鹌鹑模型的降脂作用[J].中国药学杂志,1995:30(11):656-659.
[75]李长龄,李雅芳,侯中林.血脂康的毒性试验研究[J].中国药理学会通讯,1995;12:121.
[76]王俊显,苏梅者,陆宗良,等.血脂康胶囊治疗高脂血症临床观察[J].中国实验方剂学杂志,1995;1(1):37-41.
[77]寇文怠,陆宗良,郭静萱,等.血脂康对原发性高脂血症的临床疗效[J].中华内科杂志,1997:36(8):529-531.
[78]血脂康调整血脂对冠心病二级预防研究协作组.中国冠心病二级预防研究。中华心血管病杂志,2005;33(2):109-115.
[79]吴研.对高脂血症“病在血液,根在脾胃”的认识[J].中医杂志,2004;45(2):155
[80]宋剑南,刘东远.高脂血症与中医痰浊关系的实验研究[J].中国中医基础医学杂志,1995;1(1):49-51.
[81]刘松林,王平,张茂林,等.痰邪致病机理的现代研究思路与方法探讨[J].中医杂志,2003;44(1):5-7.